Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253629 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT01253629 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 175 participants.
The verdict
NCT01253629, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.
Interventions
- DRUG Placebo
- DRUG AFQ056
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253629
The ClinicalTrials.gov registry entry for NCT01253629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01253629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253629 about?
NCT01253629 is a clinical study titled "Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome". This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.
What is the current status of trial NCT01253629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2010-11. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01253629?
The interventions under investigation include: Placebo (DRUG), AFQ056 (DRUG).
Who is sponsoring clinical trial NCT01253629?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.